Medicare extends home hospital care before safety study is done

What it does

This bill extends Medicare's experimental 'Hospital Care at Home' program—which allows certain patients to receive acute inpatient-level care in their homes instead of hospitals—through September 30, 2030. It also requires the Department of Health and Human Services to conduct a detailed study by September 2028 comparing outcomes, costs, quality, and patient experience between home-based care and traditional hospital inpatient care, with $2.5 million appropriated for the study. The bill does not change eligibility or coverage rules; it extends an existing waiver and mandates evidence-gathering on whether the program works.

Why we flagged it

The bill's core function is to extend an existing Medicare waiver program and require a study on its effects. It is neither a deregulation nor a carve-out, but a conditional extension tied to evidence-gathering—a pragmatic but cautious approach to an experimental program.

What the text implies

• The waiver extension runs through 2030 while the mandated study is not due until September 2028, meaning the program will operate for two additional years after the study concludes with no requirement to act on findings—creating a lag between evidence and policy adjustment.
• The bill does not specify what happens if the study finds poor outcomes, cost overruns, or safety concerns; there is no automatic sunset or adjustment mechanism tied to study results.

The full analysis lists 5 implications of this text.

Who stands to gain

home health agencies and telehealth providers (expanded service volume under extended waiver); hospitals participating in the program (potential cost savings if home care is cheaper than inpatien; medical equipment suppliers (home monitoring, telehealth infrastructure)